Molecular Partners AGMLLCF 25 Cyclically Adjusted PB Ratio is 0.76 as of Jul. 04, 2026, which is 7% below its 10-year median of 0.82. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 701 Biotechnology companies, Molecular Partners AG ranks better than 69.33% on this metric.
The historical rank and industry rank for Molecular Partners AG's Cyclically Adjusted PB Ratio or its related term are showing as below:
MLLCF'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.63 Med: 0.82 Max: 1.24
Current: 0.69
During the past 13 years, Molecular Partners AG's highest Cyclically Adjusted PB Ratio was 1.24. The lowest was 0.63. And the median was 0.82.
MLLCF's Cyclically Adjusted PB Ratio is ranked better than 69.33% of 701
companies
in the Biotechnology industry
Industry Median: 1.58
vs MLLCF: 0.69
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Molecular Partners AG's adjusted book value per share data of for the fiscal year that ended in Dec25 was $2.695. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.75 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Molecular Partners AG (OTCPK:MLLCF) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Molecular Partners AG Cyclically Adjusted PB Ratio Related Terms
Molecular Partners AG Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG Cyclically Adjusted PB Ratio Chart
MLLCF vs VRTX, REGN, ALNY: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Molecular Partners AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Cyclically Adjusted PB Ratio falls into.
Molecular Partners AG Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.76 mean?
Molecular Partners AG (MLLCF) has a Cyclically Adjusted PB Ratio of 0.76 as of Jul. 04, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Molecular Partners AG and its competitors. This is near median its historical median of 0.82. Over the past decade, Molecular Partners AG's Cyclically Adjusted PB Ratio has ranged from 0.63 to 1.24. According to the industry distribution chart, Molecular Partners AG ranks #215 out of 701 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Molecular Partners AG's Cyclically Adjusted PB Ratio too high?
Molecular Partners AG's current Cyclically Adjusted PB Ratio of 0.76 is near median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 1.24. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.58. Molecular Partners AG's value of 0.76 is 51.9% below this industry median. Based on the distribution chart, Molecular Partners AG ranks #215 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #215 out of 701 companies for Cyclically Adjusted PB Ratio. This puts Molecular Partners AG in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.58. Molecular Partners AG's value of 0.76 is 51.9% below this benchmark. Historically, Molecular Partners AG's own Cyclically Adjusted PB Ratio has ranged from 0.63 to 1.24 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 1.58, Molecular Partners AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.58, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Cyclically Adjusted PB Ratio of 0.76 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Cyclically Adjusted PB Ratio is 0.76, which is near median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $3.60 — trading 757.1% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.76, which is near median its 10-year median of 0.82 and 51.9% below the Biotechnology industry median of 1.58. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Cyclically Adjusted PB Ratio is 0.76 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 757.1% above its estimated GF Value™ of $0.42.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Cyclically Adjusted PB Ratio: 0.76 (near median its 10-year median of 0.82)
GF Value™: $0.42 vs. price of $3.60 (757.1% above fair value)
Industry Position: 51.9% below the Biotechnology median (#215 of 701)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
